Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 15;37(9):1425-1429.
doi: 10.1097/QAD.0000000000003591. Epub 2023 May 3.

Effectiveness of topical cidofovir for treatment of refractory anal high-grade squamous intraepithelial lesion

Joaquin Burgos  1 , David Campany  2 , Jorge Garcia  1 , Stefania Landolfi  3 , Vicenç Falcó  1 , Adrià Curran  1
Affiliations

Effectiveness of topical cidofovir for treatment of refractory anal high-grade squamous intraepithelial lesion

Joaquin Burgos et al. AIDS. .

Abstract

Objectives: Ablative electrocautery is effective treating anal high-grade squamous intraepithelial lesions (HSILs). However, persistence or recurrence of the HSIL despite ablative sessions is not uncommon. The aim of this study is to assess the feasibility of topical cidofovir as salvage therapy for the management of refractory HSIL.

Design: A prospective uncontrolled unicenter study of men and transgender people who have sex with men with HIV who had a refractory intra-anal HSIL after ablative treatments and who received topical cidofovir (ointment at 1%, auto-applicated, three times a week, a total of 8 weeks) as salvage therapy. Effectiveness was evaluated on-treatment defining response as resolution or regression to low-grade lesion of HSIL in the biopsy posttreatment. Tolerance and recurrences were recorded.

Results: From 2017 to 2022, 23 patients with refractory intra-anal HSIL (78.3% persistent lesions, 39% affecting > 50% of circumference, and a median of six previous ablative sessions) were treated with topical cidofovir. A response was observed in 16 of 23 patients [69.5% (95% confidence interval (95% CI) 50.8-88.4)]. Local tolerance was reported as regular or bad in 13 patients (52.2%), requiring modification of the treatment in eight patients (three early discontinuation and five dose reduction). Non-serious side effects were reported. After a median follow-up of 30.3 months, two of the 16 patients with a response developed recurrent HSIL [recurrence rate, 25.4% at 12 months (95% CI, 0-35)].

Conclusion: Topical cidofovir could be a good option in the management of anal HSIL due to its good effectiveness, low recurrence rate, and acceptable tolerance even in difficult-to-treat lesions.

PubMed Disclaimer

References

    1. Deshmukh AA, Suk R, Shiels MS, Sonawane K, Nyitray AG, Liu Y, et al. Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001–2015 . J Natl Cancer Inst 2020; 112:829–838.
    1. Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et al. A meta-analysis of anal cancer incidence by risk group: toward a unified anal cancer risk scale . Int J Cancer 2021; 148:38–47.
    1. Berry JM, Jay N, Cranston RD, Darragh TM, Holly EA, Welton ML, et al. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men . Int J Cancer 2014; 134:1147–1155.
    1. Leeds IL, Fang SH. Anal cancer and intraepithelial neoplasia screening: a review . World J Gastrointest Surg 2016; 8:41–51.
    1. Palefsky JM, Lee JY, Jay N, Darragh TM, Dunlevy HA, Rosa-Cunha I, et al. Treatment of anal high-grade squamous intraepithelial lesions to prevent anal cancer . N Engl J Med 2022; 386:2273–2282.